NANALYSIS SCIENTIFIC CORP (NSCI.CA) Fundamental Analysis & Valuation

TSX-V:NSCI • CA63000Y1034

Current stock price

0.145 CAD
0 (0%)
Last:

This NSCI.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. NSCI.CA Profitability Analysis

1.1 Basic Checks

  • In the past year NSCI has reported negative net income.
  • NSCI had a positive operating cash flow in the past year.
  • NSCI had negative earnings in each of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: NSCI reported negative operating cash flow in multiple years.
NSCI.CA Yearly Net Income VS EBIT VS OCF VS FCFNSCI.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5M -10M -15M

1.2 Ratios

  • NSCI has a Return On Assets of -14.73%. This is amongst the best in the industry. NSCI outperforms 86.67% of its industry peers.
  • NSCI has a Return On Equity of -42.16%. This is amongst the best in the industry. NSCI outperforms 86.67% of its industry peers.
Industry RankSector Rank
ROA -14.73%
ROE -42.16%
ROIC N/A
ROA(3y)-25.65%
ROA(5y)-19.16%
ROE(3y)-66.23%
ROE(5y)-46.86%
ROIC(3y)N/A
ROIC(5y)N/A
NSCI.CA Yearly ROA, ROE, ROICNSCI.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40 -60 -80

1.3 Margins

  • NSCI has a worse Gross Margin (24.83%) than 73.33% of its industry peers.
  • NSCI's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for NSCI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 24.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-17.91%
GM growth 5Y-17.67%
NSCI.CA Yearly Profit, Operating, Gross MarginsNSCI.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. NSCI.CA Health Analysis

2.1 Basic Checks

  • NSCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, NSCI has more shares outstanding
  • Compared to 5 years ago, NSCI has more shares outstanding
  • The debt/assets ratio for NSCI is higher compared to a year ago.
NSCI.CA Yearly Shares OutstandingNSCI.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
NSCI.CA Yearly Total Debt VS Total AssetsNSCI.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

2.2 Solvency

  • NSCI has an Altman-Z score of -0.78. This is a bad value and indicates that NSCI is not financially healthy and even has some risk of bankruptcy.
  • NSCI's Altman-Z score of -0.78 is fine compared to the rest of the industry. NSCI outperforms 80.00% of its industry peers.
  • NSCI has a debt to FCF ratio of 11.21. This is a negative value and a sign of low solvency as NSCI would need 11.21 years to pay back of all of its debts.
  • NSCI has a better Debt to FCF ratio (11.21) than 100.00% of its industry peers.
  • A Debt/Equity ratio of 0.73 indicates that NSCI is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.73, NSCI is in the better half of the industry, outperforming 73.33% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF 11.21
Altman-Z -0.78
ROIC/WACCN/A
WACC5.97%
NSCI.CA Yearly LT Debt VS Equity VS FCFNSCI.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 0.97 indicates that NSCI may have some problems paying its short term obligations.
  • NSCI's Current ratio of 0.97 is fine compared to the rest of the industry. NSCI outperforms 66.67% of its industry peers.
  • A Quick Ratio of 0.76 indicates that NSCI may have some problems paying its short term obligations.
  • The Quick ratio of NSCI (0.76) is better than 73.33% of its industry peers.
Industry RankSector Rank
Current Ratio 0.97
Quick Ratio 0.76
NSCI.CA Yearly Current Assets VS Current LiabilitesNSCI.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. NSCI.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 60.34% over the past year.
  • The Revenue for NSCI has decreased by -11.79% in the past year. This is quite bad
  • NSCI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 38.50% yearly.
EPS 1Y (TTM)60.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.59%
Revenue 1Y (TTM)-11.79%
Revenue growth 3Y17.37%
Revenue growth 5Y38.5%
Sales Q2Q%-13.13%

3.2 Future

  • The Earnings Per Share is expected to grow by 55.53% on average over the next years. This is a very strong growth
  • NSCI is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.03% yearly.
EPS Next Y97.78%
EPS Next 2Y67.33%
EPS Next 3Y55.53%
EPS Next 5YN/A
Revenue Next Year4.3%
Revenue Next 2Y5.58%
Revenue Next 3Y6.03%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
NSCI.CA Yearly Revenue VS EstimatesNSCI.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 10M 20M 30M 40M
NSCI.CA Yearly EPS VS EstimatesNSCI.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 0.05 -0.05 -0.1 -0.15

More info and screens

Find the best growth stocksShow best growing peers

2

4. NSCI.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NSCI. In the last year negative earnings were reported.
  • Also next year NSCI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NSCI.CA Price Earnings VS Forward Price EarningsNSCI.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100

4.2 Price Multiples

  • NSCI's Price/Free Cash Flow ratio is rather cheap when compared to the industry. NSCI is cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 12.8
EV/EBITDA N/A
NSCI.CA Per share dataNSCI.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2

4.3 Compensation for Growth

  • NSCI's earnings are expected to grow with 55.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y67.33%
EPS Next 3Y55.53%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NSCI.CA Dividend Analysis

5.1 Amount

  • NSCI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NSCI.CA Fundamentals: All Metrics, Ratios and Statistics

NANALYSIS SCIENTIFIC CORP

TSX-V:NSCI (4/27/2026, 7:00:00 PM)

0.145

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-08
Earnings (Next)05-26
Inst Owners7.08%
Inst Owner ChangeN/A
Ins Owners3.54%
Ins Owner ChangeN/A
Market Cap20.08M
Revenue(TTM)40.13M
Net Income(TTM)-5.66M
Analysts80
Price Target0.51 (251.72%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-13.36%
Min Revenue beat(2)-14.08%
Max Revenue beat(2)-12.64%
Revenue beat(4)0
Avg Revenue beat(4)-10.45%
Min Revenue beat(4)-14.08%
Max Revenue beat(4)-7.14%
Revenue beat(8)4
Avg Revenue beat(8)10.68%
Revenue beat(12)6
Avg Revenue beat(12)5.17%
Revenue beat(16)7
Avg Revenue beat(16)-0.09%
PT rev (1m)-20%
PT rev (3m)-20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.5
P/FCF 12.8
P/OCF 5.82
P/B 1.5
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.05
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)0.01
FCFY7.81%
OCF(TTM)0.02
OCFY17.2%
SpS0.29
BVpS0.1
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -14.73%
ROE -42.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 24.83%
FCFM 3.91%
ROA(3y)-25.65%
ROA(5y)-19.16%
ROE(3y)-66.23%
ROE(5y)-46.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-17.91%
GM growth 5Y-17.67%
F-Score4
Asset Turnover1.04
Health
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF 11.21
Debt/EBITDA N/A
Cap/Depr 54.98%
Cap/Sales 4.69%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.97
Quick Ratio 0.76
Altman-Z -0.78
F-Score4
WACC5.97%
ROIC/WACCN/A
Cap/Depr(3y)64.52%
Cap/Depr(5y)93.09%
Cap/Sales(3y)8.3%
Cap/Sales(5y)14.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.59%
EPS Next Y97.78%
EPS Next 2Y67.33%
EPS Next 3Y55.53%
EPS Next 5YN/A
Revenue 1Y (TTM)-11.79%
Revenue growth 3Y17.37%
Revenue growth 5Y38.5%
Sales Q2Q%-13.13%
Revenue Next Year4.3%
Revenue Next 2Y5.58%
Revenue Next 3Y6.03%
Revenue Next 5YN/A
EBIT growth 1Y-6.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year236.61%
EBIT Next 3Y75.29%
EBIT Next 5YN/A
FCF growth 1Y11.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.79%
OCF growth 3YN/A
OCF growth 5YN/A

NANALYSIS SCIENTIFIC CORP / NSCI.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NANALYSIS SCIENTIFIC CORP (NSCI.CA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to NSCI.CA.


What is the valuation status of NANALYSIS SCIENTIFIC CORP (NSCI.CA) stock?

ChartMill assigns a valuation rating of 2 / 10 to NANALYSIS SCIENTIFIC CORP (NSCI.CA). This can be considered as Overvalued.


Can you provide the profitability details for NANALYSIS SCIENTIFIC CORP?

NANALYSIS SCIENTIFIC CORP (NSCI.CA) has a profitability rating of 2 / 10.


What is the earnings growth outlook for NANALYSIS SCIENTIFIC CORP?

The Earnings per Share (EPS) of NANALYSIS SCIENTIFIC CORP (NSCI.CA) is expected to grow by 97.78% in the next year.